Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Vanguard Short Term Corporate Bond ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Vanguard Short Term Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $78.52, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

VCSHXBI
Sector
Fixed IncomeBroad Market / Factor
52-Week High
$80.20$164.28
52-Week Low
$78.41$86.92

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Short Term Corporate Bond ETF

VCSH trades at $78.58, up 0.11% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a 4.8% yield with recent dividends of $0.29-$0.30, though credit spreads are tight. News highlights institutional activity, including Apella Capital reducing its stake by 5.6% in Q2 2026 (SEC filing, August 7, 2026).

Outlook is cautious due to unattractive entry points and limited upside from rate cuts, per Seeking Alpha (July 27, 2026). Risks include credit spread widening and competition from alternatives like BSV. The short 2.7-year duration offers some downside protection, but yield advantages may narrow.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About Vanguard Short Term Corporate Bond ETF

VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.

Read more on VCSH

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI